• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Friday 11/16/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

HempMeds

  • 2:11 PM

    SAN DIEGO, Jan. 31, 2017, MJNA, /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company in the United States, is proud to announce the progress made by subsidiary HempMeds® Mexico upon the one-year anniversary of the first-ever import permit for RSHO-X™ into Mexico. HempMeds® Mexico is the first company to receive government import permits for the cannabidiol (CBD) oil product RSHO-X™ via the Mexican Health Department, COFEPRIS. The decision by COFEPRIS ushered in a historic newfound

    Read more
  • 7:04 PM

    Company’s Subsidiary HempMeds(R) Mexico Begins Taking Private Orders for RSHO(TM) in Colombia, Showcases Products at Expo Mede Weed 2016 in City of Medellin SAN DIEGO, CA–MJNA, (Marketwired – November 28, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA) announced today that its subsidiary HempMeds® Mexico, the first and only company with approval from COFEPRIS to legally import a cannabis product into Mexico, has begun distributing Real Scientific Hemp Oil™ (RSHO™) to Colombia. This announcement comes at a pivotal time as

    Read more
  • 3:54 PM

    SAN DIEGO, Jan. 14, 2016, MJNA (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (the “Company”) (OTC Pink:MJNA) is pleased to announce the Company has significantly reduced its debt obligation from $24 million at the close of the third quarter (ending 9/30/2015) to approximately $10 million at the close of the fourth quarter (ending 12/31/2015), a reduction of approximately $14 million. The Company also acquired and consolidated several of its partnerships including 93.4% of HempMeds® Brasil™, LLC and the remaining 20% of HempMeds® PX that Medical Marijuana, Inc. did

    Read more
  • 3:17 PM

    SILVER SPRING, Md., Oct. 19, 2015, PMCB, OTCQB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its upcoming clinical trial designed to determine whether its pancreatic cancer treatment (Cell-in-a-Box® capsules + low-doses ifosfamide chemotherapy) can satisfy a critical unmet medical need for patients with pancreatic cancer will be conducted in the United States with additional study sites

    Read more
  • 2:29 PM

    NEW YORK, July 9, 2015 /PRNewswire/ — Small Cap IR issues report: PharmaCyte Biotech, Inc. (OTCQB: PMCB) “Cell-in-a-Box” platform exhibits significant potential. Any cell type could potentially be implanted in the body without need for administration of any drugs that decrease the body’s immune response. This is important for potential therapies and will dramatically increase versatility and value of this technology into the future.  The PMCB platform is a cellulose based “bead” containing live cells. The porous nature of the

    Read more
  • 4:23 PM

    SILVER SPRING, Md., Jan 06, 2015 (GLOBE NEWSWIRE via COMTEX) — Nuvilex, Inc. (OTCQB:NVLX) today announced that its Chief Executive Officer (CEO), Kenneth L Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., will be attending the 2015 Gastrointestinal Cancers Symposium, “Bridging Cancer Biology to Clinical GI Oncology,” to be held in the Moscone West Convention Center in San Francisco, California, January 15-17, 2015. Nuvilex’s CEO, Kenneth L. Waggoner, stated, “Our attendance at this pivotal Symposium, which is

    Read more
Public Wire Banner